• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NANOSTRING TECHNOLOGIES, INC. PROSIGNA; CLASSIFIER, PROGNOSTIC, RECURRENCE RISK ASSESSMENT, RNA GENE EXPRESSION, BREAST

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NANOSTRING TECHNOLOGIES, INC. PROSIGNA; CLASSIFIER, PROGNOSTIC, RECURRENCE RISK ASSESSMENT, RNA GENE EXPRESSION, BREAST Back to Search Results
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Type  Injury  
Event Description
Nano[invalid]products branded as veracyte don't work.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROSIGNA
Type of Device
CLASSIFIER, PROGNOSTIC, RECURRENCE RISK ASSESSMENT, RNA GENE EXPRESSION, BREAST
Manufacturer (Section D)
NANOSTRING TECHNOLOGIES, INC.
MDR Report Key17855426
MDR Text Key324809806
Report NumberMW5146345
Device Sequence Number1
Product Code NYI
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Unknown
Type of Report Initial
Report Date 09/26/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/29/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Was Device Available for Evaluation? No
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Life Threatening;
-
-